| 1A. Paolo Fundarò | | | 1B. | | | 1C. Srinivas Akkaraju, M.D., Ph.D. | | | ||
| 1D. Luca Benatti, Ph.D. | | | 1E. Daniel | | | 1F. Keith Gottesdiener, M.D. | | | ||
| 1G. Nancy | | | 1H. | | | 1I. | | | ||
| 1J. | | | 1K. Glenn Sblendorio | | | | | | | |
| | | Page | | |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 7 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 16 | | | |
| | | | 16 | | | |
| | | | 16 | | | |
| | | | 19 | | | |
| | | | 19 | | | |
| | | | 20 | | | |
| | | | 20 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 25 | | | |
| | | | 25 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| | ||||||
| | | | | | ||
| | | | ||||
| |
| | | Page | | |||
| | | | 32 | | | |
| | | | 33 | | | |
| | | | 35 | | | |
| | | | 35 | | | |
| | | | 37 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | ||||
| | ||||||
| | | | | | ||
| | | | | | ||
| | | | 75 | | | |
| | | | 76 | | | |
| | | | | | ||
| | | | ||||
| | ||||||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | |
Director | | Age | | Director Since | | | Age | | Director Since | | ||||||||||||||||
Paolo Fundarò(1) | | | | 46 | | | | | 2006 | | | | | | 47 | | | | | 2006 | | | ||||
Mark Pruzanski, M.D. | | | | 52 | | | | | 2002 | | | |||||||||||||||
Jerome Durso | | | | 53 | | | | | 2021 | | | |||||||||||||||
Srinivas Akkaraju, M.D., Ph.D.(2) | | | | 52 | | | | | 2012 | | | | | | 53 | | | | | 2012 | | | ||||
Luca Benatti, Ph.D.(2)(3) | | | | 59 | | | | | 2014 | | | | | | 60 | | | | | 2014 | | | ||||
Daniel Bradbury(3)(4) | | | | 59 | | | | | 2016 | | | | | | 60 | | | | | 2016 | | | ||||
Keith Gottesdiener, M.D.(2) | | | | 66 | | | | | 2016 | | | | | | 67 | | | | | 2016 | | | ||||
Nancy Miller-Rich(5) | | | | 61 | | | | | 2018 | | | | | | 62 | | | | | 2018 | | | ||||
Gino Santini(4)(5)(6) | | | | 63 | | | | | 2015 | | | |||||||||||||||
Mark Pruzanski, M.D. | | | | 53 | | | | | 2002 | | | |||||||||||||||
Dagmar Rosa-Bjorkeson | | | | 57 | | | | | 2021 | | | |||||||||||||||
Gino Santini(4)(5)(6) | | | | 64 | | | | | 2015 | | | |||||||||||||||
Glenn Sblendorio(4) | | | | 64 | | | | | 2014 | | | | | | 65 | | | | | 2014 | | | ||||
Daniel Welch(3)(5) | | | | 62 | | | | | 2015 | | |
| Eligible Participants | | | All current employees except executive officers; directors, consultants, and former employees are not eligible | |
| Type of Exchange | | | Options for Options | |
| Eligible Options | | | Options with exercise prices above both (1) the 52-week high for Company stock and (2) 1.5 times the current trading price of our shares, in each case as of a date shortly prior to the commencement date of the offer | |
| Options are excluded from participating in the offer that are scheduled to expire before the exchange closes | | |||
| Options that were granted on or after February 15, 2020 are excluded from participating in the offer | | |||
| Elections | | | Employees may elect to exchange individual grants; however, if an employee elects to exchange a specific grant, all options granted on the same date must be exchanged | |
| Term of Replacement Grant | | | All replacement options will have a six and one-half year maximum term | |
| Vesting of Replacement Grant | | | Replacement awards will vest on the first anniversary of the replacement grant (with respect to vested options that are exchanged) and on the second anniversary of the replacement grant (with respect to unvested options that are exchanged), subject in each case to continued employment | |
| Plan to Be Issued Under | | | Replacement options will be issued under the 2012 Equity Incentive Plan; excess shares resulting from exchange will not be returned to the plan pool | |
| Illustrative Exchange Ratios | | | Exchange ratios depend on the value of the underwater options, which are grouped to simplify administration; exchange ratios are expected to range from 1.25-to-1 to 4.5 -to-1 (described in more detail below) | |
| Total Grants Eligible for Exchange, Price, and Term | | | Options to purchase approximately 967,000 shares with a weighted average exercise price of $103.83 and a weighted average remaining term of 6.78 years are expected to be eligible for the exchange program | |
| Total Replacement Grants, Price and Term | | | Assuming 100% participation, approximately 626,000 options are expected to be granted as replacement options with an exercise price based on the closing price as of the date of the exchange and a maximum term of six and one half years | |
Per Share Exercise Price ($) | | | Number of Outstanding Options in Range | | | Weighted Average Exercise Price ($) | | | Weighted Average Remaining Term | | | Exchange Ratio | | | New Options Issuable (assuming full participation) | | |||||||||||||||
55.59 – 75.00 | | | | | 235,000 | | | | | | 61.57 | | | | | | 6.72 | | | | | | 1.25 – 1 | | | | | | 188,000 | | |
75.01 – 115.00 | | | | | 576,000 | | | | | | 103.07 | | | | | | 7.46 | | | | | | 1.50 – 1 | | | | | | 384,000 | | |
115.01 – 125.00 | | | | | 60,000 | | | | | | 120.62 | | | | | | 5.26 | | | | | | 2.00 – 1 | | | | | | 30,000 | | |
125+ | | | | | 96,000 | | | | | | 201.20 | | | | | | 3.85 | | | | | | 4.00 – 1 | | | | | | 24,000 | | |
Name | | | Board | | | Audit | | | Compensation | | | Nominating and Governance | | | Research and Development | |
Paolo Fundarò | | | C | | | – | | | – | | | – | | | – | |
Srinivas Akkaraju, M.D., Ph.D. | | | M | | | – | | | – | | | – | | | M | |
Luca Benatti, Ph.D. | | | M | | | – | | | – | | | M | | | C | |
Daniel Bradbury | | | M | | | M | | | – | | | M | | | – | |
Keith Gottesdiener, M.D. | | | M | | | – | | | – | | | – | | | M | |
Nancy Miller-Rich | | | M | | | – | | | M | | | – | | | – | |
Gino Santini | | | M | | | M | | | C | | | – | | | – | |
Glenn Sblendorio | | | M | | | C | | | – | | | – | | | – | |
Daniel Welch | | | M | | | – | | | M | | | C | | | – | |
Membership | | Chairperson | | Other Members | | | Chairperson | | Other Members | | ||||||||||||||||
Board of Directors. | | | $ | 80,000 | | | | $ | 50,000 | | | |||||||||||||||
Board of Directors | | | $ | 80,000 | | | | $ | 50,000 | | | |||||||||||||||
Audit Committee | | | $ | 20,000 | | | | $ | 10,000 | | | | | $ | 20,000 | | | | $ | 10,000 | | | ||||
Compensation Committee | | | $ | 15,000 | | | | $ | 7,500 | | | | | $ | 15,000 | | | | $ | 7,500 | | | ||||
Nominating and Governance Committee | | | $ | 10,000 | | | | $ | 5,000 | | | | | $ | 10,000 | | | | $ | 5,000 | | | ||||
Research and Development Committee | | | $ | 10,000 | | | | $ | 5,000 | | | | | $ | 10,000 | | | | $ | 5,000 | | |
Name | | Fees Earned or Paid in Cash ($) | | Stock Awards ($)(10) | | Option Awards ($)(10) | | Total ($) | | | Fees Earned or Paid in Cash ($)(1) | | Stock Awards ($)(2) | | Option Awards ($)(2) | | Total ($) | | ||||||||||||||||||||||||||||||||
Paolo Fundarò | | | | 80,000(1) | | | | | 129,133 | | | | | 132,223 | | | | | 341,356 | | | | | | 80,000 | | | | | 116,020 | | | | | 132,254 | | | | | 328,274 | | | ||||||||
Srinivas Akkaraju, M.D., Ph.D. | | | | 55,000(2) | | | | | 129,133 | | | | | 132,223 | | | | | 316,356 | | | | | | 55,000 | | | | | 116,020 | | | | | 132,254 | | | | | 303,274 | | | ||||||||
Luca Benatti, Ph.D. | | | | 65,000(3) | | | | | 129,133 | | | | | 132,223 | | | | | 326,356 | | | | | | 65,000 | | | | | 116,020 | | | | | 132,254 | | | | | 313,274 | | | ||||||||
Daniel Bradbury | | | | 65,000(4) | | | | | 129,133 | | | | | 132,223 | | | | | 326,356 | | | | | | 65,000 | | | | | 116,020 | | | | | 132,254 | | | | | 313,274 | | | ||||||||
Keith Gottesdiener, M.D. | | | | 55,000(5) | | | | | 129,133 | | | | | 132,223 | | | | | 316,356 | | | | | | 55,000 | | | | | 116,020 | | | | | 132,254 | | | | | 303,274 | | | ||||||||
Nancy Miller-Rich | | | | 57,500(6) | | | | | 129,133 | | | | | 132,223 | | | | | 318,856 | | | | | | 57,500 | | | | | 116,020 | | | | | 132,254 | | | | | 305,774 | | | ||||||||
Gino Santini | | | | 75,000(7) | | | | | 129,133 | | | | | 132,223 | | | | | 336,356 | | | | | | 75,000 | | | | | 116,020 | | | | | 132,254 | | | | | 323,274 | | | ||||||||
Glenn Sblendorio | | | | 70,000(8) | | | | | 129,133 | | | | | 132,223 | | | | | 331,356 | | | | | | 70,000 | | | | | 116,020 | | | | | 132,254 | | | | | 318,274 | | | ||||||||
Daniel Welch | | | | 67,500(9) | | | | | 129,133 | | | | | 132,223 | | | | | 328,856 | | | | | | 67,500 | | | | | 116,020 | | | | | 132,254 | | | | | 315,774 | | |
Name | | | Shares Subject to Stock Options | | | Restricted Stock Units | | ||||||
Paolo Fundarò | | | | | 15,527 | | | | | | 1,595 | | |
Srinivas Akkaraju, M.D., Ph.D. | | | | | 14,526 | | | | | | 1,595 | | |
Luca Benatti, Ph.D. | | | | | 13,823 | | | | | | 1,595 | | |
Daniel Bradbury | | | | | 13,120 | | | | | | 1,595 | | |
Keith Gottesdiener, M.D. | | | | | 13,120 | | | | | | 1,595 | | |
Nancy Miller-Rich | | | | | 12,824 | | | | | | 3,053 | | |
Gino Santini | | | | | 15,022 | | | | | | 1,595 | | |
Glenn Sblendorio | | | | | 13,823 | | | | | | 1,595 | | |
Daniel Welch | | | | | 15,022 | | | | | | 1,595 | | |
| | Shares Beneficially Owned(9) | | | Shares Beneficially Owned(11) | | ||||||||||||||||||||
Name and Address | | Number of Shares | | Percentage of Common Stock | | | Number of Shares | | Percentage of Common Stock | | ||||||||||||||||
5% Stockholders: | | | | | | | | | | | | | | | | | | | | | | | ||||
Genextra S.p.A.(1) | | | | 6,095,578 | | | | | 18.5% | | | | | | 4,000,000 | | | | | 12.1% | | | ||||
FMR LLC(2) | | | | 4,919,116 | | | | | 14.9 % | | | | | | 3,726,914 | | | | | 11.2% | | | ||||
BlackRock, Inc.(3) | | | | 2,314,468 | | | | | 7.0 % | | | |||||||||||||||
The Vanguard Group(4) | | | | 2,296,438 | | | | | 7.0 % | | | |||||||||||||||
The Vanguard Group(3) | | | | 2,828,955 | | | | | 8.5% | | | |||||||||||||||
State Street Corporation(4) | | | | 2,550,750 | | | | | 7.7% | | | |||||||||||||||
BlackRock, Inc.(5) | | | | 2,498,408 | | | | | 7.5% | | | |||||||||||||||
First Trust Portfolios L.P.(6) | | | | 1,975,601 | | | | | 6.0% | | | |||||||||||||||
Directors and Executive Officers: | | | | | | | | | | | | | | | | | | | | | | | ||||
Paolo Fundarò(5) | | | | 6,129,142 | | | | | 18.6% | | | |||||||||||||||
Mark Pruzanski, M.D.(6) | | | | 787,855 | | | | | 2.4% | | | |||||||||||||||
Paolo Fundarò(1) | | | | 4,036,555 | | | | | 12.2% | | | |||||||||||||||
Jerome Durso | | | | 73,967 | | | | | * | | | |||||||||||||||
Srinivas Akkaraju, M.D., Ph.D.(7) | | | | 438,344 | | | | | 1.3% | | | | | | 678,335 | | | | | 2.0% | | | ||||
Luca Benatti, Ph.D. | | | | 21,553 | | | | | * | | | | | | 24,544 | | | | | * | | | ||||
Daniel Bradbury(8) | | | | 26,723 | | | | | * | | | | | | 29,714 | | | | | * | | | ||||
Keith Gottesdiener, M.D. | | | | 20,082 | | | | | * | | | | | | 23,073 | | | | | * | | | ||||
Nancy Miller-Rich | | | | 14,809 | | | | | * | | | | | | 20,362 | | | | | * | | | ||||
Mark Pruzanski, M.D.(9) | | | | 856,763 | | | | | 2.6% | | | |||||||||||||||
Dagmar Rosa-Bjorkeson | | | | — | | | | | — | | | |||||||||||||||
Gino Santini | | | | 20,910 | | | | | * | | | | | | 23,901 | | | | | * | | | ||||
Glenn Sblendorio | | | | 19,513 | | | | | * | | | | | | 22,504 | | | | | * | | | ||||
Daniel Welch | | | | 20,091 | | | | | * | | | | | | 23,082 | | | | | * | | | ||||
Jerome Durso. | | | | 50,857 | | | | | * | | | |||||||||||||||
Sandip Kapadia | | | | 54,264 | | | | | * | | | |||||||||||||||
Richard Kim | | | | 32,751 | | | | | * | | | |||||||||||||||
Ryan Sullivan | | | | 30,456 | | | | | * | | | |||||||||||||||
All directors and executive officers as group (19 persons) | | | | 7,812,414 | | | | | 23.7% | | | |||||||||||||||
Sandip Kapadia(10) | | | | 85,458 | | | | | * | | | |||||||||||||||
Richard Kim(10) | | | | 48,563 | | | | | * | | | |||||||||||||||
Lisa Bright(10) | | | | 79,919 | | | | | * | | | |||||||||||||||
Ryan Sullivan(10) | | | | 24,708 | | | | | * | | | |||||||||||||||
Christian Weyer, M.D., M.A.S. | | | | 32,077 | | | | | * | | | |||||||||||||||
All current directors and executive officers as a group (20 persons) | | | | 5,944,358 | | | | | 17.9% | | |
Name | | | Age | | | Position | |
| | ||||||
| | Chief | |||||
| |||||||
Gail Cawkwell, M.D., Ph.D. | | | | | SVP, Medical Affairs, Safety & Pharmacovigilance; Acting Chief Medical Officer | | |
Lisa DeFrancesco | | | 42 | | | SVP, | |
David Ford | | | | | Chief Human Resources Officer | | |
| | ||||||
| | General Counsel | | ||||
Linda Richardson | | | 57 | | | EVP, Chief Commercial Officer | |
Rocco Venezia | | | 45 | | | Chief Accounting Officer; Acting Chief Financial Officer and | |
Christian Weyer, M.D., M.A.S. | | | | | EVP, Research & Development | |
Name | | | Title | |
Mark Pruzanski, M.D. | | | President and Chief Executive Officer | |
Jerome Durso | | | Chief Operating Officer | |
Sandip Kapadia | | | Chief Financial Officer and Treasurer | |
| | | ||
Lisa Bright | | | President, International | |
Ryan Sullivan | | | General Counsel and Secretary | |
| | |
| | | | |
| | | | |
| | ✓ ✓ | | |
| | * Except for Dr. Pruzanski, whose TSR PSUs vest pursuant to the terms of his Retirement and Consulting Agreement. See “Executive Compensation—Retirement and Consulting Agreement”. | | |
| | | | |||||||||||||
| | ✓ | | | | | | |||||||||
| | ✓ | | | | | | |||||||||
| | ✓ | | | | | | |||||||||
| | ✓ | | | | | | |||||||||
| | ✓ | | | | Advanced | | | ||||||||
| | ✓ | | | | Further Developed INT-787. We have been evaluating our | | | ||||||||
| | ✓ | | | | Extended the Term of a Key Patent in Our Intellectual Property Portfolio; Commenced Enforcement Action Against ANDA Filers. In 2020, the U.S. | | | ||||||||
| | ✓ | | | | Developed Leadership Team and DEI Initiatives. Our leadership team, led by President and Chief Executive Officer Jerome Durso (who succeeded to | | |
| | CEO | | | ||||||||||||||
| | Our CEO | | | | | ||||||||||||
| | Mr. Durso succeeds as our | | | | | | |||||||||||
| | ✓ | | | | Market-Based | | | ||||||||||
| | ✓ | | | | Significant Performance Elements. | | | ||||||||||
| | ✓ | | | | | | |||||||||||
| | ✓ | | | | Executive Leadership. Our | | | ||||||||||
| | | | |||||||||||||||
| | Overview. We are committed to establishing and maintaining an open and transparent dialogue with our stockholders with respect to executive compensation and important governance matters. Each year, we engage with our stockholders to request feedback regarding our executive compensation program and other governance matters of importance to our stockholders. Stockholder feedback is then reported to our Compensation Committee and Nominating and Governance Committee and to the full Board for consideration. | | | ||||||||||||||
| | Stockholder Advisory Vote on Executive Compensation. Each year, our stockholders are provided the opportunity to cast an advisory vote on the compensation of our named executive officers (a “say-on-pay” vote), and our Compensation Committee considers the outcome of the prior year’s say-on-pay vote when making decisions relating to the compensation of our named executive officers and our executive compensation program. Our | | |
| | our stockholder engagement activities. In | | | ||||||||||||
| | Stockholder Feedback. We believe that our outreach was well received, and many of the stockholders that we contacted in |
and refine our compensation programs as we | | | ||||||||||||||
| | Commitment to Future Outreach. We believe that stockholder engagement is important, and our Compensation Committee will continue to consider stockholder feedback, future say-on-pay votes, and relevant market developments in order to determine whether any subsequent changes to our executive compensation program are warranted. We expect to continue our outreach efforts with respect to executive compensation and important governance matters in future years in order to ensure that we collect stockholder feedback for the consideration of our Compensation Committee, Nominating and Governance Committee, and | | | ||||||||||||
| | | | |||||||||||||
| | What We Do | | | ||||||||||||
| | ✓ | | | | Independent Chairman and | | | ||||||||
| | ✓ | | | | Additional Independent Board Leadership and Diversity. Gino Santini serves as our Board’s Lead Independent Director, which we believe enhances our Board governance structure and contributes to the overall effectiveness of our Board. In addition, in April 2018 and April 2021, we appointed Nancy Miller-Rich and Dagmar Rosa-Bjorkeson, respectively, as | | | ||||||||
| | ✓ | | | | Independent Compensation Committee. Our Compensation Committee, which is composed entirely of independent directors, provides independent oversight of our compensation programs. | | | ||||||||
| | ✓ | | | | Independent Compensation Consultant. Our Compensation Committee uses an independent executive compensation consulting firm that reports directly to the committee. | | | ||||||||
| | ✓ | | | | Annual Compensation Review and Analysis. Our Compensation Committee conducts an annual assessment of executive compensation to ensure that we provide competitive compensation packages to attract, retain, reward, and incentivize our executive management team to achieve success for us and our stockholders. | | | ||||||||
| | ✓ | | | | Multiple Performance Elements. In accordance with our performance-based compensation | | |
| | | | | | philosophy, our executive compensation program incorporates multiple performance elements, including target-based cash incentive bonuses payable upon the achievement of corporate goals and individual performance, and long-term equity incentive compensation, a substantial portion of which consists of stock options and TSR PSUs. | | | ||||||||
| | ✓ | | | | Significant Portion of Compensation Is at Risk. Under our executive compensation program, a significant portion of compensation is “at risk” based on our performance, including annual cash incentive bonuses, and long-term incentive compensation in the form of equity awards, to align the interests of our executive officers and stockholders. | | | ||||||||
| | ✓ | | | | Market Benchmarking and Use of Reference Peer Group. Our Compensation Committee, with the assistance of its independent compensation consultant, annually analyzes similar life science companies to identify a relevant group of peer companies for purposes of ensuring the reasonableness and competitiveness of our executive compensation program. | | | ||||||||
| | ✓ | | | | Stock Ownership Requirements. We have adopted minimum stock ownership guidelines for our Board, | | |
| | ✓ | | | | Clawback Policy. We have adopted a clawback policy that permits the Company to recover from any current or former executive officer, including any named executive officer, whose fraud or intentional misconduct contributes to the circumstances requiring the Company to prepare an accounting restatement due to material non-compliance of the Company with any financial reporting requirement under U.S. federal securities laws, up to 100% of any incentive-based compensation received by such officer from the Company during the one-year period preceding the date on which the Company is required to prepare such accounting restatement. | | | ||||||||
| | ✓ | | | | Corporate Governance Guidelines. In 2019, we adopted corporate governance guidelines reflecting our Board’s commitment to building long-term stockholder value with an emphasis on corporate governance. The Nominating and Governance Committee periodically reviews the adequacy and effectiveness of our corporate governance guidelines and recommends any proposed changes to the Board for approval. In February 2021, we amended those guidelines to emphasize our commitment to diversity, equity, and inclusion (“DEI”). | | |
| | What We Don’t Do | | | ||||||||||||
| | ✘ | | | | No excise tax gross-ups. We have not provided, or committed to provide, excise tax gross-ups to any of our named executive officers. | | | ||||||||
| | ✘ | | | | No change in control “windfalls”. The change in control protections for our named executive officers are limited to “double-trigger” arrangements, which require both a change in control and a qualifying termination of employment, or in the case of TSR PSUs, vesting, if at all, based on our TSR performance relative to that of our TSR Peer Group through the month preceding the month in which the change in control occurs. | | | ||||||||
| | ✘ | | | | Limited perquisites. Our named executive officers generally receive the same benefits as are available to all of our salaried employees, with limited recurring exceptions primarily consisting of fully-paid health insurance premiums. | | | ||||||||
| | ✘ | | | | No automatic or guaranteed annual salary increases. We do not provide for any formulaic or guaranteed base salary increases for our named executive officers. | | | ||||||||
| | ✘ | | | | No guaranteed bonuses or annual equity grants. We do not provide guaranteed bonuses or annual equity grants to our named executive officers. In addition, our Compensation Committee determined to maintain the | | | ||||||||
| | ✘ | | | | No hedging or pledging of Company stock. Our named executive officers and other employees are restricted from engaging in speculative trading activities, including hedging or pledging their company securities as collateral. | | |
| ACADIA Pharmaceuticals Inc. | | | | | Radius Health, Inc. | | |
| | | Ionis Pharmaceuticals, Inc. | | | |||
| ||||||||
| Alnylam Pharmaceuticals, Inc. | | | Neurocrine Biosciences, Inc. | | | | |
| bluebird bio, Inc. | | | Omeros Corporation | | | | |
| Exelixis, Inc. | | | Pacira Pharmaceuticals, Inc. | | | | |
| FibroGen, Inc. | | | | | United Therapeutics Corporation | | |
| Halozyme Therapeutics, Inc. | | | PTC Therapeutics, Inc. | | | | |
Named Executive Officer | | | 2020 Salary(1) | | | 2019 Salary | | | Change from 2019 | | |||||||||
Mark Pruzanski, M.D. | | | | $ | 759,992 | | | | | $ | 734,292 | | | | | | 3.50% | | |
Jerome Durso | | | | $ | 601,913 | | | | | $ | 573,250 | | | | | | 5.00% | | |
Sandip Kapadia | | | | $ | 478,023 | | | | | $ | 464,100 | | | | | | 3.00% | | |
Richard Kim | | | | $ | 457,294 | | | | | $ | 442,900 | | | | | | 3.25% | | |
Lisa Bright(2) | | | | $ | 481,910 | | | | | $ | 465,613 | | | | | | 3.50% | | |
Ryan Sullivan | | | | $ | 461,113 | | | | | $ | 445,520 | | | | | | 3.50% | | |
Christian Weyer, M.D., M.A.S. | | | | $ | 488,011 | | | | | $ | 472,650 | | | | | | 3.25% | | |
2019 Corporate Goal Summary | | | Relative Weighting | | | Assessed Achievement | |
NASH Program | | | 60% | | | 59% | |
Includes specified activities and milestones related to: | | | | ||||
• the delivery of topline results from the planned 18-month interim analysis of our pivotal Phase 3 clinical trial of OCA in patients with liver fibrosis due to NASH, known as the REGENERATE trial, and the timing thereof • the acceptance of our NDA in NASH in the United States and the timing thereof • the timely completion of launch preparation and organization ramp-up activities to support a launch of OCA in liver fibrosis due to NASH in the United States, if approved, including the establishment of marketing and medical plans and the creation and appropriate staffing of the launch organization | | | | ||||
PBC Commercial Program | | | 30% | | | 41% | |
Includes specified commercial milestones such as: | | | | ||||
• the achievement of $230 million in worldwide annual net sales of Ocaliva • the achievement of commercial contribution targets in PBC | | | | ||||
Pipeline and New Products | | | 10% | | | 9% | |
Includes specified activities and milestones related to: | | | | | | | |
• the initiation of a Phase 2 study of OCA/bezafibrate combination in PBC • the development and implementation of a pipeline expansion strategy | | | | | | ||
Total | | | 100% | | | 109% | |
2020 Corporate Goal Summary | | | Relative Weighting | | | Assessed Achievement | |
NASH Program | | | 50% | | | 15% | |
Includes specified activities and milestones related to: | | | | ||||
• securing FDA approval for OCA in NASH • executing the launch of OCA in NASH in accordance with the Company’s launch preparation plans • ensuring that launch plans are in place, including with respect to targeting, organizational capabilities, competencies and team engagement, and that appropriate launch preparations are executed in a timely way | | | | ||||
PBC Commercial Program | | | 25% | | | 30% | |
Includes specified commercial milestone as follows: | | | | ||||
• achieve pre-specified Ocaliva total unit sales for 2020 | | | | ||||
Pipeline | | | 15% | | | 15% | |
Includes specified activities and milestones related to: | | | | | | | |
• manufacturing selected fixed-dose combination (“FDC”) formulation for potential use and study • timing and completion of key activities required to prepare for first-in-human clinical trial of INT-787 | | | | ||||
Organization | | | 10% | | | 10% | |
Includes specified activities and milestones related to: | | | | | | | |
• effective organizational management related to human resources, capabilities, and competencies for executing on organizational priorities, including potential launch of OCA for liver fibrosis due to NASH • recruiting and training of appropriate staff • appropriate management of expenses and headcount | | | | | | ||
Total | | | 100% | | | 70% | |
| | | 2019 Cash Incentive Bonus | | |||||||||||||||||||||||||||
Named Executive Officer | | | Target (as % of Base Salary) | | | Corporate Goal Achievement Level | | | Individual Goal Achievement Level | | | Aggregate Achievement (as % of Base Salary) | | | Payment | | |||||||||||||||
Dr. Mark Pruzanski | | | | | 70% | | | | | | 109% | | | | | | — | | | | | | 76% | | | | | $ | 560,265 | | |
Sandip Kapadia | | | | | 50% | | | | | | 109% | | | | | | 100% | | | | | | 55% | | | | | $ | 252,935 | | |
Jerome Durso | | | | | 50% | | | | | | 109% | | | | | | 115% | | | | | | 63% | | | | | $ | 359,284 | | |
Ryan Sullivan | | | | | 50% | | | | | | 109% | | | | | | 110% | | | | | | 60% | | | | | $ | 267,089 | | |
Richard Kim | | | | | 50% | | | | | | 109% | | | | | | 110% | | | | | | 60% | | | | | $ | 265,519 | | |
| | | 2020 Cash Incentive Bonus | | |||||||||||||||||||||||||||
Named Executive Officer | | | Target (as % of Base Salary) | | | Corporate Goal Achievement Level | | | Individual Goal Achievement Level | | | Aggregate Achievement (as % of Base Salary) | | | Payment ($) | | |||||||||||||||
Mark Pruzanski, M.D. | | | | | 70% | | | | | | N/A | | | | | | — | | | | | | N/A | | | | | | 531,995(1) | | |
Jerome Durso | | | | | 50% | | | | | | 70% | | | | | | 110% | | | | | | 39% | | | | | | 231,737 | | |
Sandip Kapadia | | | | | 50% | | | | | | 70% | | | | | | 110% | | | | | | 39% | | | | | | 184,039 | | |
Richard Kim | | | | | 50% | | | | | | 70% | | | | | | 105% | | | | | | 37% | | | | | | 168,056 | | |
Lisa Bright | | | | | 50% | | | | | | — | | | | | | — | | | | | | — | | | | | | 240,955(2) | | |
Ryan Sullivan | | | | | 50% | | | | | | — | | | | | | — | | | | | | — | | | | | | —(3) | | |
Christian Weyer, M.D., M.A.S. | | | | | 50% | | | | | | 70% | | | | | | 100% | | | | | | 35% | | | | | | 170,804 | | |
Relative TSR | | | Vesting Percentage | |
Below 25th Percentile | | | 0% | |
25th Percentile | | | 50% | |
50th Percentile | | | 100% | |
75th Percentile and Above | | | 150% | |
Named Executive Officer | | TSR PSUs | | Stock Options | | Restricted Stock Units | | | TSR PSUs | | Stock Options | | Restricted Stock Units | | ||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | 23,300 | | | | | 13,700 | | | | | 8,500 | | | ||||||||||||||||||||||
Mark Pruzanski, M.D. | | | | 25,800 | | | | | 17,700 | | | | | 10,800 | | | ||||||||||||||||||||||
Jerome Durso | | | | 8,500 | | | | | 17,400 | | | | | 10,600 | | | ||||||||||||||||||||||
Sandip Kapadia | | | | 3,600 | | | | | 7,200 | | | | | 4,500 | | | | | | 4,500 | | | | | 9,200 | | | | | 5,600 | | | ||||||
Jerome Durso | | | | 7,500 | | | | | 15,200 | | | | | 9,400 | | | ||||||||||||||||||||||
Richard Kim | | | | 4,300 | | | | | 8,800 | | | | | 5,400 | | | ||||||||||||||||||||||
Lisa Bright | | | | 3,800 | | | | | 7,900 | | | | | 4,800 | | | ||||||||||||||||||||||
Ryan Sullivan | | | | 5,300 | | | | | 10,700 | | | | | 6,600 | | | | | | 4,500 | | | | | 9,200 | | | | | 5,600 | | | ||||||
Richard Kim | | | | 3,200 | | | | | 6,400 | | | | | 4,000 | | | ||||||||||||||||||||||
Christian Weyer, M.D., M.A.S. | | | | 3,800 | | | | | 7,900 | | | | | 4,800 | | |
Named Executive Officer | | | 2021 Salary | | | 2020 Salary | | | Change from 2020 | | |||||||||
Jerome Durso | | | | $ | 690,750 | | | | | $ | 601,913 | | | | | | 14.76% | | |
Sandip Kapadia* | | | | $ | 497,140 | | | | | $ | 478,023 | | | | | | 4.00% | | |
Richard Kim* | | | | $ | 457,294 | | | | | $ | 457,294 | | | | | | — | | |
Christian Weyer, M.D., M.A.S. | | | | $ | 504,000 | | | | | $ | 488,011 | | | | | | 3.28% | | |
Named Executive Officer | | | Target Cash | ||||||||||
(as % of Base Salary) | | ||||||||||||
Jerome Durso | |||||||||||||
| | | | 70% | | | |
Sandip | |||||||
| | | | 50% | | | |
Richard | | | | | 50% | | |
Christian Weyer, M.D., M.A.S. | | | | | 50% | | |
Named Executive Officer | | | TSR PSUs | | | Stock Options | | | Restricted Stock Units | | |||||||||
Dr. Mark Pruzanski | | | | | 25,800 | | | | | | 17,700 | | | | | | 10,800 | | |
Sandip Kapadia | | | | | 4,500 | | | | | | 9,200 | | | | | | 5,600 | | |
Jerome Durso | | | | | 8,500 | | | | | | 17,400 | | | | | | 10,600 | | |
Ryan Sullivan | | | | | 4,500 | | | | | | 9,200 | | | | | | 5,600 | | |
Richard Kim | | | | | 4,300 | | | | | | 8,800 | | | | | | 5,400 | | |
Named Executive Officer | | | TSR PSUs | | | Stock Options | | | Restricted Stock Units | | |||||||||
Jerome Durso | | | | | 110,300 | | | | | | 72,000 | | | | | | 46,000 | | |
Sandip Kapadia* | | | | | 13,800 | | | | | | 26,900 | | | | | | 17,200 | | |
Richard Kim* | | | | | — | | | | | | — | | | | | | — | | |
Christian Weyer, M.D., M.A.S. | | | | | 10,100 | | | | | | 19,700 | | | | | | 12,600 | | |
Name and Principal Position | | Year(1) | | Salary ($)(2) | | Bonus ($)(3) | | Stock Awards ($)(4) | | Option Awards ($)(4) | | Non-Equity Incentive Plan Compensation ($)(5) | | All Other Compensation ($)(6) | | Total ($) | | | Year(1) | | Salary ($)(2) | | Bonus ($)(3) | | Stock Awards ($)(4) | | Option Awards ($)(4) | | Non-Equity Incentive Plan Compensation ($)(5) | | All Other Compensation ($)(6) | | Total ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dr. Mark Pruzanski President and Chief Executive Officer | | | | | 2019 | | | | | 734,292 | | | | | — | | | | | 4,197,742 | | | | | 1,116,118 | | | | | 560,265 | | | | | 7,368 | | | | | 6,615,785 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 702,000 | | | | | — | | | | | 1,667,718 | | | | | 1,705,358 | | | | | 442,260 | | | | | 8,623 | | | | | 4,525,960 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2017 | | | | | 675,000 | | | | | — | | | | | 2,486,576 | | | | | 2,583,556 | | | | | 401,625 | | | | | 7,930 | | | | | 6,154,687 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sandip Kapadia Chief Financial Officer and Treasurer | | | | | 2019 | | | | | 464,100 | | | | | — | | | | | 1,001,664 | | | | | 586,573 | | | | | 252,935 | | | | | 21,368 | | | | | 2,326,640 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 442,000 | | | | | — | | | | | 790,164 | | | | | 393,544 | | | | | 228,735 | | | | | 22,403 | | | | | 1,876,846 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2017 | | | | | 425,000 | | | | | — | | | | | 750,260 | | | | | 749,231 | | | | | 188,594 | | | | | 23,930 | | | | | 2,137,016 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jerome Durso Chief Operating Officer | | | | | 2019 | | | | | 573,250 | | | | | — | | | | | 2,089,570 | | | | | 1,238,321 | | | | | 359,284 | | | | | 21,368 | | | | | 4,281,793 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 540,800 | | | | | — | | | | | 1,554,326 | | | | | 775,844 | | | | | 292,032 | | | | | 22,403 | | | | | 3,185,406 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2017 | | | | | 441,333 | | | | | — | | | | | 1,738,950 | | | | | 1,395,217 | | | | | 260,000 | | | | | 26,765 | | | | | 3,862,266 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ryan Sullivan General Counsel and Secretary | | | | | 2019 | | | | | 445,520 | | | | | — | | | | | 1,471,902 | | | | | 871,713 | | | | | 267,089 | | | | | 21,368 | | | | | 3,077,592 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 376,158 | | | | | — | | | | | 1,239,112 | | | | | 1,190,351 | | | | | 229,122 | | | | | 173,437 | | | | | 3,208,180 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Richard Kim President, U.S. Commercial & Strategic Marketing | | | | 2019 | | | | | 442,900 | | | | | 202,800 | | | | | 890,368 | | | | | 521,398 | | | | | 265,519 | | | | | 76,343 | | | | | 2,399,328 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mark Pruzanski, M.D., President and Chief Executive Officer | | | | | 2020 | | | | | 757,850 | | | | | — | | | | | 4,113,504 | | | | | 1,015,996 | | | | | 531,995 | | | | | 7,660 | | | | | 6,427,005 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 734,292 | | | | | — | | | | | 4,197,742 | | | | | 1,116,118 | | | | | 560,265 | | | | | 7,368 | | | | | 6,615,785 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 702,000 | | | | | — | | | | | 1,667,718 | | | | | 1,705,358 | | | | | 442,260 | | | | | 8,623 | | | | | 4,525,960 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jerome Durso, Chief Operating Officer | | | | | 2020 | | | | | 599,524 | | | | | — | | | | | 2,057,016 | | | | | 998,776 | | | | | 231,737 | | | | | 21,910 | | | | | 3,908,963 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 573,250 | | | | | — | | | | | 2,089,570 | | | | | 1,238,321 | | | | | 359,284 | | | | | 21,368 | | | | | 4,281,793 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 540,800 | | | | | — | | | | | 1,554,326 | | | | | 775,844 | | | | | 292,032 | | | | | 22,403 | | | | | 3,185,406 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sandip Kapadia, Chief Financial Officer and Treasurer | | | | | 2020 | | | | | 476,863 | | | | | — | | | | | 1,087,836 | | | | | 528,088 | | | | | 184,039 | | | | | 21,910 | | | | | 2,298,736 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 464,100 | | | | | — | | | | | 1,001,664 | | | | | 586,573 | | | | | 252,935 | | | | | 21,368 | | | | | 2,326,640 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 442,000 | | | | | — | | | | | 790,164 | | | | | 393,544 | | | | | 228,735 | | | | | 22,403 | | | | | 1,876,846 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Richard Kim, Former President, U.S. Commercial & Strategic Marketing | | | | | 2020 | | | | | 456,095 | | | | | — | | | | | 1,044,360 | | | | | 505,128 | | | | | 168,056 | | | | | 79,211 | | | | | 2,252,850 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 442,900 | | | | | 202,800 | | | | | 890,368 | | | | | 521,398 | | | | | 265,519 | | | | | 76,343 | | | | | 2,399,328 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lisa Bright, Former President, International (7) | | | | 2020 | | | | | 480,552 | | | | | — | | | | | 925,704 | | | | | 453,467 | | | | | 240,955 | | | | | 139,106 | | | | | 2,239,784 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ryan Sullivan, Former General Counsel and Secretary | | | | | 2020 | | | | | 437,107 | | | | | — | | | | | 1,087,836 | | | | | 528,088 | | | | | — | | | | | 89,942 | | | | | 2,142,973 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 445,520 | | | | | — | | | | | 1,471,902 | | | | | 871,713 | | | | | 267,089 | | | | | 21,368 | | | | | 3,077,592 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2018 | | | | | 376,158 | | | | | — | | | | | 1,239,112 | | | | | 1,190,351 | | | | | 229,122 | | | | | 173,437 | | | | | 3,208,180 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Christian Weyer, M.D., M.A.S., EVP, Research & Development | | | | 2020 | | | | | 486,731 | | | | | — | | | | | 925,704 | | | | | 453,467 | | | | | 170,804 | | | | | 21,910 | | | | | 2,058,616 | | |
Name | | Contributions Under 401(k) Plan ($)(i) | | Health Insurance ($)(ii) | | Miscellaneous ($)(iii) | | | Contributions Under Retirement Plans ($)(i) | | Health Insurance ($)(ii) | | Miscellaneous ($) | | ||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | — | | | | | 7,368 | | | | | — | | | ||||||||||||||||||||||
Mark Pruzanski, M.D. | | | | — | | | | | 7,660 | | | | | — | | | ||||||||||||||||||||||
Jerome Durso | | | | 14,250 | | | | | 7,660 | | | | | — | | | ||||||||||||||||||||||
Sandip Kapadia | | | | 14,000 | | | | | 7,368 | | | | | — | | | | | | 14,250 | | | | | 7,660 | | | | | — | | | ||||||
Jerome Durso | | | | 14,000 | | | | | 7,368 | | | | | — | | | ||||||||||||||||||||||
Ryan Sullivan | | | | 14,000 | | | | | 7,368 | | | | | — | | | ||||||||||||||||||||||
Richard Kim | | | | 14,000 | | | | | 7,368 | | | | | 54,975 | | | ||||||||||||||||||||||
Richard Kim(iii) | | | | 14,250 | | | | | 7,660 | | | | | 57,301 | | | ||||||||||||||||||||||
Lisa Bright(iv) | | | | 86,499 | | | | | 18,168 | | | | | 34,439 | | | ||||||||||||||||||||||
Ryan Sullivan(v) | | | | 14,250 | | | | | 7,660 | | | | | 68,032 | | | ||||||||||||||||||||||
Christian Weyer, M.D., M.A.S. | | | | 14,250 | | | | | 7,660 | | | | | — | | |
Name | | Grant Date | | Estimated Future Payout Under Non-Equity Incentive Plan Awards Target ($)(2) | | | Estimated Future Payouts Under Equity Incentive Plan Awards(3) | | | All Other Stock Awards: Number of Shares of Stock (#)(5) | | All Other Option Awards: Number of Securities Underlying Options (#)(6) | | Exercise or Base Price of Option Awards ($/Sh)(7) | | Grant Date Fair Value of Stock and Option Awards ($)(8) | | | Grant Date(1) | | Estimated Future Payout Under Non-Equity Incentive Plan Awards Target ($)(2) | | | Estimated Future Payouts Under Equity Incentive Plan Awards(3) | | | All Other Stock Awards: Number of Shares of Stock (#)(5) | | All Other Option Awards: Number of Securities Underlying Options (#)(6) | | Exercise or Base Price of Option Awards ($/Sh)(7) | | Grant Date Fair Value of Stock and Option Awards ($)(8) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Threshold (#)(4) | | Target (#) | | Maximum (#) | | | Threshold (#)(4) | | Target (#) | | Maximum (#) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | | — | | | | | 514,004 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | 11,650 | | | | | 23,300 | | | | | 34,950 | | | | | — | | | | | — | | | | | — | | | | | 3,255,942 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 8,500 | | | | | 13,700 | | | | | 110.80 | | | | | 941,800 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 1,116,118 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Mark Pruzanski, M.D. | | | | | — | | | | | 531,995 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 12,900 | | | | | 25,800 | | | | | 38,700 | | | | | — | | | | | — | | | | | — | | | | | 3,037,176 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,800 | | | | | — | | | | | — | | | | | 1,076,328 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 17,700 | | | | | 57.40 | | | | | 1,015,996 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jerome Durso | | | | | — | | | | | 300,956 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 4,250 | | | | | 8,500 | | | | | 12,750 | | | | | — | | | | | — | | | | | — | | | | | 1,000,620 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,600 | | | | | — | | | | | — | | | | | 1,056,396 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 17,400 | | | | | 57.40 | | | | | 998,776 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sandip Kapadia | | | | | — | | | | | 232,050 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | — | | | | | 239,012 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | 1,800 | | | | | 3,600 | | | | | 5,400 | | | | | — | | | | | — | | | | | — | | | | | 503,064 | | | | | | 01/23/20 | | | | | — | | | | | 2,250 | | | | | 4,500 | | | | | 6,750 | | | | | — | | | | | — | | | | | — | | | | | 529,740 | | | |||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 4,500 | | | | | — | | | | | — | | | | | 498,600 | | | | | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 5,600 | | | | | — | | | | | — | | | | | 558,096 | | | |||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 7,200 | | | | | 110.80 | | | | | 586,573 | | | | | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 9,200 | | | | | 57.40 | | | | | 528,088 | | | |||||||||||||||||||
Jerome Durso | | | | | — | | | | | 286,625 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | 3,750 | | | | | 7,500 | | | | | 11,250 | | | | | — | | | | | — | | | | | — | | | | | 1,048,050 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 9,400 | | | | | — | | | | | — | | | | | 1,041,520 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 15,200 | | | | | 110.80 | | | | | 1,238,321 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Richard Kim | | | | | — | | | | | 228,647 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 2,150 | | | | | 4,300 | | | | | 6,450 | | | | | — | | | | | — | | | | | — | | | | | 506,196 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 5,400 | | | | | — | | | | | — | | | | | 538,164 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 8,800 | | | | | 57.40 | | | | | 505,128 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lisa Bright | | | | | — | | | | | 240,955 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 1,900 | | | | | 3,800 | | | | | 5,700 | | | | | — | | | | | — | | | | | — | | | | | 447,336 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 4,800 | | | | | — | | | | | — | | | | | 478,368 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 7,900 | | | | | 57.40 | | | | | 453,467 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ryan Sullivan | | | | | — | | | | | 222,760 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | 2,650 | | | | | 5,300 | | | | | 7,950 | | | | | | | | | | — | | | | | — | | | | | 740,622 | | | | | | 01/23/20 | | | | | — | | | | | 2,250 | | | | | 4,500 | | | | | 6,750 | | | | | — | | | | | — | | | | | — | | | | | 529,740 | | | |||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 6,600 | | | | | 10,700 | | | | | 110.80 | | | | | 731,280 | | | | | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 5,600 | | | | | — | | | | | — | | | | | 558,096 | | | |||||||||||||||||||
| | | 01/16/19(1) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | 871,713 | | | | | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 9,200 | | | | | 57.40 | | | | | 528,088 | | | |||||||||||||||||||
Richard Kim | | | | | — | | | | | 221,450 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | 1,600 | | | | | 3,200 | | | | | 4,800 | | | | | | | | | | — | | | | | — | | | | | 447,168 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 4,000 | | | | | | | | | | | | | | | 443,200 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/16/19(1) | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 6,400 | | | | | 110.80 | | | | | 521,398 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Christian Weyer, M.D., M.A.S | | | | | — | | | | | 244,006 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | 1,900 | | | | | 3,800 | | | | | 5,750 | | | | | — | | | | | — | | | | | — | | | | | 447,336 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 4,800 | | | | | — | | | | | — | | | | | 478,368 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/23/20 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 7,900 | | | | | 57.40 | | | | | 453,467 | | |
| | | Option Awards | | | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||||
Name | | | Number of Securities Underlying Unexercised Options (#) Exercisable | | | Number of Securities Underlying Unexercised Options (#) Unexercisable(13) | | | Option Exercise Price ($) | | | Option Expiration Date | | | | Number of Shares or Units of Stock That Have Not Vested (#)(14) | | | Market Value of Shares or Units of Stock That Have Not Vested ($) | | | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#)(22) | | | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | | ||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | | 30,084(1) | | | | | | — | | | | | | 21.50 | | | | | | 11/16/22 | | | | | | | 1,456(15) | | | | | | 180,428 | | | | | | 35,100(23) | | | | | | 4,349,592 | | |
| | | 62,595(2) | | | | | | — | | | | | | 31.90 | | | | | | 05/07/23 | | | | | | | 7,250(16) | | | | | | 898,420 | | | | | | 34,950(24) | | | | | | 4,331,004 | | | ||
| | | 5,733(3) | | | | | | — | | | | | | 266.01 | | | | | | 04/11/24 | | | | | | | 6,375(17) | | | | | | 789,990 | | | | | | — | | | | | | — | | | ||
| | | — | | | | | | 5,733(3) | | | | | | 266.01 | | | | | | 04/11/24 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 32,550(4) | | | | | | — | | | | | | 161.16 | | | | | | 10/01/25 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 29,865(5) | | | | | | 635(5) | | | | | | 94.29 | | | | | | 02/11/26 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 29,167(6) | | | | | | 10,833(6) | | | | | | 107.18 | | | | | | 02/01/27 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 21,801(7) | | | | | | 23,699(7) | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
| | | 3,425(8) | | | | | | 10,275(8) | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | ||
Sandip Kapadia | | | | | 15,375(9) | | | | | | 2,625(9) | | | | | | 146.36 | | | | | | 07/01/26 | | | | | | | 2,812(18) | | | | | | 348,463 | | | | | | 8,100(23) | | | | | | 1,003,752 | | |
| | | 8,458(6) | | | | | | 3,142(6) | | | | | | 107.18 | | | | | | 02/01/27 | | | | | | | 2,187(16) | | | | | | 271,013 | | | | | | 5,400(24) | | | | | | 669,168 | | | ||
| | | 5,030(7) | | | | | | 5,470(7) | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 3,882(19) | | | | | | 481,057 | | | | | | — | | | | | | — | | | ||
| | | 1,800(8) | | | | | | 5,400(8) | | | | | | 10.80 | | | | | | 01/16/29 | | | | | | | 3,375(17) | | | | | | 418,230 | | | | | | — | | | | | | — | | | ||
Jerome Durso | | | | | 14,167(10) | | | | | | 5,833(10) | | | | | | 115.93 | | | | | | 02/23/27 | | | | | | | 4,687(20) | | | | | | 580,813 | | | | | | 15,900(23) | | | | | | 1,970,328 | | |
| | | 9,918(7) | | | | | | 10,782(7) | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 7,650(19) | | | | | | 947,988 | | | | | | 11,250(24) | | | | | | 1,394,100 | | | ||
| | | 3,800(8) | | | | | | 11,400(8) | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 7,050(17) | | | | | | 873,636 | | | | | | — | | | | | | — | | | ||
Ryan Sullivan | | | | | 7,353(11) | | | | | | 19,122(11) | | | | | | 53.41 | | | | | | 02/13/28 | | | | | | | 13,050(21) | | | | | | 1,617,156 | | | | | | 7,950(24) | | | | | | 985,164 | | |
| | | 2,675(8) | | | | | | 8,025(8) | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 4,950(17) | | | | | | 613,404 | | | | | | — | | | | | | — | | | ||
Richard Kim | | | | | 4,395(12) | | | | | | — | | | | | | 277.61 | | | | | | 07/18/25 | | | | | | | 127(15) | | | | | | 15,738 | | | | | | 6,750(23) | | | | | | 836,460 | | |
| | | 4,015(5) | | | | | | 85(5) | | | | | | 94.29 | | | | | | 02/11/26 | | | | | | | 1,469(16) | | | | | | 182,038 | | | | | | 4,800(24) | | | | | | 594,816 | | | ||
| | | 5,363(6) | | | | | | 2,437(6) | | | | | | 107.18 | | | | | | 02/01/27 | | | | | | | 3,263(19) | | | | | | 404,350 | | | | | | — | | | | | | — | | | ||
| | | 4,216(7) | | | | | | 4,584(7) | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 3,000(17) | | | | | | 371,760 | | | | | | — | | | | | | — | | | ||
| | | 1,600(8) | | | | | | 4,800(8) | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | Option awards | | | | Stock awards | | ||||||||||||||||||||||||||||||||||||||||||||||||
Name | | | Number of securities underlying unexercised options (#) exercisable | | | Number of securities underlying unexercised options (#) unexercisable(1) | | | Equity incentive plan awards: number of securities underlying unexercised unearned options (#) | | | Option exercise price ($) | | | Option expiration date | | | | Number of shares or units of stock that have not vested (#)(2) | | | Market value of shares or units of stock that have not vested ($) | | | Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#)(3) | | | Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($) | | |||||||||||||||||||||||||||
(a) | | | (b) | | | (c) | | | (d) | | | (e) | | | (f) | | | | (g) | | | (h) | | | (i) | | | (j) | | |||||||||||||||||||||||||||
Mark Pruzanski, M.D.(7) | | | | | 30,084(4a) | | | | | | — | | | | | | — | | | | | | 21.50 | | | | | | 11/16/22 | | | | | | | 1,450(5a) | | | | | | 35,815 | | | | | | 32,039(6a) | | | | | | 791,363 | | |
| | | | | 62,595(4b) | | | | | | — | | | | | | — | | | | | | 31.90 | | | | | | 05/07/23 | | | | | | | 3,896(5e) | | | | | | 96,231 | | | | | | 35,475(6b) | | | | | | 876,233 | | |
| | | | | 5,733(4c) | | | | | | — | | | | | | — | | | | | | 266.01 | | | | | | 04/11/24 | | | | | | | 7,425(5f) | | | | | | 183,398 | | | | | | — | | | | | | — | | |
| | | | | 32,550(4d) | | | | | | — | | | | | | — | | | | | | 161.16 | | | | | | 10/01/25 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 30,500(4e) | | | | | | — | | | | | | — | | | | | | 94.29 | | | | | | 02/11/26 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 39,167(4f) | | | | | | 833 | | | | | | — | | | | | | 107.18 | | | | | | 02/01/27 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 34,123(4g) | | | | | | 11,377 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 7,420(4h) | | | | | | 6,280 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 5,531(4i) | | | | | | 12,169 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Jerome Durso | | | | | 19,167(4j) | | | | | | 833 | | | | | | — | | | | | | 115.93 | | | | | | 02/23/27 | | | | | | | 937(5b) | | | | | | 23,144 | | | | | | 3,750(6a) | | | | | | 92,625 | | |
| | | | | 15,093(4g) | | | | | | 5,607 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 4,250(5d) | | | | | | 104,975 | | | | | | 4,250(6b) | | | | | | 104,975 | | |
| | | | | 7,600(4h) | | | | | | 7,600 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 4,700(5e) | | | | | | 116,090 | | | | | | — | | | | | | — | | |
| | | | | 4,350(4i) | | | | | | 13,050 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | 7,950(5f) | | | | | | 196,365 | | | | | | — | | | | | | — | | |
Sandip Kapadia | | | | | 18,000(4k) | | | | | | — | | | | | | — | | | | | | 146.36 | | | | | | 07/01/26 | | | | | | | 437(5a) | | | | | | 10,794 | | | | | | 1,800(6a) | | | | | | 44,460 | | |
| | | | | 11,358(4f) | | | | | | 242 | | | | | | — | | | | | | 107.18 | | | | | | 02/01/27 | | | | | | | 2,157(5d) | | | | | | 53,278 | | | | | | 2,250(6b) | | | | | | 55,575 | | |
| | | | | 7,655(4g) | | | | | | 2,845 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 2,250(5e) | | | | | | 55,575 | | | | | | — | | | | | | — | | |
| | | | | 3,600(4h) | | | | | | 3,600 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 4,200(5f) | | | | | | 103,740 | | | | | | — | | | | | | — | | |
| | | | | 2,300(4i) | | | | | | 6,900 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Richard Kim | | | | | 4,395(4L) | | | | | | — | | | | | | — | | | | | | 277.61 | | | | | | 07/18/25 | | | | | | | 294(5a) | | | | | | 7,262 | | | | | | 1,600(6a) | | | | | | 39,520 | | |
| | | | | 4,100(4e) | | | | | | — | | | | | | — | | | | | | 94.29 | | | | | | 02/11/26 | | | | | | | 1,813(5d) | | | | | | 44,781 | | | | | | 2,150(6b) | | | | | | 53,105 | | |
| | | | | 7,313(4f) | | | | | | 487 | | | | | | — | | | | | | 107.18 | | | | | | 02/01/27 | | | | | | | 2,000(5e) | | | | | | 49,400 | | | | | | — | | | | | | — | | |
| | | | | 6,416(4g) | | | | | | 2,384 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 4,050(5f) | | | | | | 100,035 | | | | | | — | | | | | | — | | |
| | | | | 3,200(4h) | | | | | | 3,200 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2,200(4i) | | | | | | 6,600 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Lisa Bright(8) | | | | | 10,232(4m) | | | | | | — | | | | | | — | | | | | | 155.00 | | | | | | 01/01/22 | | | | | | | 294(5a) | | | | | | 7,262 | | | | | | 1,300(6a) | | | | | | 32,110 | | |
| | | | | 13,450(4d) | | | | | | — | | | | | | — | | | | | | 161.16 | | | | | | 01/01/22 | | | | | | | 1,719(5d) | | | | | | 42,459 | | | | | | 1,900(6b) | | | | | | 46,930 | | |
| | | | | 10,200(4e) | | | | | | — | | | | | | — | | | | | | 94.29 | | | | | | 01/01/22 | | | | | | | 1,650(5e) | | | | | | 40,755 | | | | | | — | | | | | | — | | |
| | | | | 7,638(4f) | | | | | | 162 | | | | | | — | | | | | | 107.18 | | | | | | 01/01/22 | | | | | | | 3,600(5f) | | | | | | 88,920 | | | | | | — | | | | | | — | | |
| | | | | 6,052(4g) | | | | | | 2,248 | | | | | | — | | | | | | 58.74 | | | | | | 01/01/22 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 2,650(4h) | | | | | | 2,650 | | | | | | — | | | | | | 110.80 | | | | | | 01/01/22 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 1,975(4i) | | | | | | 5,925 | | | | | | — | | | | | | 99.66 | | | | | | 01/01/22 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Ryan Sullivan(8) | | | | | 15,443(4n) | | | | | | — | | | | | | — | | | | | | 53.41 | | | | | | 03/11/21 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
| | | | | 5,127(4h) | | | | | | — | | | | | | — | | | | | | 110.80 | | | | | | 03/11/21 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Christian Weyer, M.D., M.A.S. | | | | | 11,504(4o) | | | | | | 5,730 | | | | | | — | | | | | | 59.12 | | | | | | 11/27/27 | | | | | | | 4,125(5c) | | | | | | 101,888 | | | | | | 1,700(6a) | | | | | | 41,990 | | |
| | | | | 2,015(4g) | | | | | | 868 | | | | | | — | | | | | | 58.74 | | | | | | 02/05/28 | | | | | | | 657(5d) | | | | | | 16,228 | | | | | | 1,900(6b) | | | | | | 46,930 | | |
| | | | | 3,400(4h) | | | | | | 3,400 | | | | | | — | | | | | | 110.80 | | | | | | 01/16/29 | | | | | | | 2,100(5e) | | | | | | 51,870 | | | | | | — | | | | ��� | | — | | |
| | | | | 1,975(4i) | | | | | | 5,925 | | | | | | — | | | | | | 99.66 | | | | | | 01/23/30 | | | | | | | 3,600(5f) | | | | | | 89,920 | | | | | | — | | | | | | — | | |
Option | | | Grant Date | | | Vesting Commencement Date | | ||||||
(a) | | | | | 11/16/12 | | | | | | — | | |
(b) | | | | | 05/07/13 | | | | | | — | | |
(c) | | | | | 04/11/14 | | | | | | — | | |
(d) | | | | | 10/01/15 | | | | | | — | | |
(e) | | | | | 02/11/16 | | | | | | — | | |
(f) | | | | | 02/01/17 | | | | | | 01/01/17 | | |
(g) | | | | | 02/05/18 | | | | | | 01/01/18 | | |
(h) | | | | | 01/16/19 | | | | | | 01/01/19 | | |
(i) | | | | | 01/23/20 | | | | | | 01/23/20 | | |
(j) | | | | | 02/23/17 | | | | | | 02/23/17 | | |
(k) | | | | | 07/01/16 | | | | | | — | | |
(L) | | | | | 07/18/15 | | | | | | — | | |
(m) | | | | | 11/24/14 | | | | | | — | | |
(n) | | | | | 02/13/18 | | | | | | 02/13/18 | | |
(o) | | | | | 11/27/17 | | | | | | 11/27/17 | | |
Shares or Units | | | Grant Date | | | Vesting Commencement Date | | ||||||
(a) | | | | | 02/01/17 | | | | | | 01/01/17 | | |
(b) | | | | | 02/23/17 | | | | | | 02/23/17 | | |
(c) | | | | | 11/27/17 | | | | | | 11/27/17 | | |
(d) | | | | | 02/05/18 | | | | | | 01/01/18 | | |
(e) | | | | | 01/16/19 | | | | | | 01/01/19 | | |
(f) | | | | | 01/23/20 | | | | | | 01/01/20 | | |
Shares or Units | | | Grant Date | | | Vesting Commencement Date | | ||||||
(a) | | | | | 01/16/19 | | | | | | 01/01/19 | | |
(b) | | | | | 01/23/20 | | | | | | 01/01/20 | | |
| | Option Awards | | Stock Awards | | | Option Awards | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||
Name | | Number of Shares Acquired on Exercise (#) | | Value Realized on Exercise ($)(1) | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting ($)(2) | | | Number of Shares Acquired on Exercise (#) | | Value Realized on Exercise ($) | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting ($)(1) | | ||||||||||||||||||||||||||||||||
Dr. Mark Pruzanski | | | | 50,517 | | | | | 4,420,527 | | | | | 14,694 | | | | | 1,396,956 | | | |||||||||||||||||||||||||||||
Mark Pruzanski, M.D. | | | | — | | | | | — | | | | | 54,346 | | | | | 1,736,397 | | | |||||||||||||||||||||||||||||
Jerome Durso | | | | — | | | | | — | | | | | 12,150 | | | | | 596,750 | | | |||||||||||||||||||||||||||||
Sandip Kapadia | | | | — | | | | | — | | | | | 9,643 | | | | | 915,168 | | | | | | — | | | | | — | | | | | 8,812 | | | | | 512,232 | | | ||||||||
Jerome Durso | | | | — | | | | | — | | | | | 12,050 | | | | | 1,160,076 | | | |||||||||||||||||||||||||||||
Richard Kim | | | | — | | | | | — | | | | | 5,102 | | | | | 251,635 | | | |||||||||||||||||||||||||||||
Lisa Bright | | | | — | | | | | — | | | | | 5,062 | | | | | 283,113 | | | |||||||||||||||||||||||||||||
Ryan Sullivan | | | | 8,825 | | | | | 278,782 | | | | | 11,800 | | | | | 1,183,334 | | | | | | — | | | | | — | | | | | 5,800 | | | | | 390,775 | | | ||||||||
Richard Kim | | | | — | | | | | — | | | | | 5,896 | | | | | 575,258 | | | |||||||||||||||||||||||||||||
Christian Weyer, M.D., M.A.S. | | | | — | | | | | — | | | | | 6,900 | | | | | 344,750 | | |
Name | | | | | | Termination Due to Death ($)(4) | | | Termination Due to Disability ($)(5) | | | Termination Without Cause or Resignation for Good Reason ($)(6) | | | Termination Without Cause or Resignation for Good Reason in Connection with a Change in Control ($)(7) | |
Jerome Durso | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | 300,956 | | | 300,956 | | | 902,869 | | | 1,805,738 | |
| | | Value of Accelerated Vesting(2) | | | 290,225 | | | 290,225 | | | 351,975 | | | 440,574 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 71,298 | |
| | | Total | | | 591,181 | | | 591,181 | | | 1,290,493 | | | 2,317,609 | |
Sandip Kapadia | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 478,023 | | | 478,023 | |
| | | Value of Accelerated Vesting(2) | | | 144,495 | | | 144,495 | | | 104,975 | | | 223,387 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 35,649 | |
| | | Total | | | 144,495 | | | 144,495 | | | 618,647 | | | 737,059 | |
Richard Kim | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 457,294 | | | 457,294 | |
| | | Value of Accelerated Vesting(2) | | | 132,145 | | | 132,145 | | | — | | | 201,478 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 35,649 | |
| | | Total | | | 132,145 | | | 132,145 | | | 492,943 | | | 694,421 | |
Christian Weyer, M.D., M.A.S. | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 488,011 | | | 488,011 | |
| | | Value of Accelerated Vesting(2) | | | 130,910 | | | 130,910 | | | 68,543 | | | 258,905 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 35,649 | |
| | | Total | | | 130,910 | | | 130,910 | | | 592,203 | | | 782,565 | |
Name | | | | | | Termination Due to Death ($)(4) | | | Termination Due to Disability ($)(5) | | | Termination Without Cause or Resignation for Good Reason ($)(6) | | | Termination Without Cause or Resignation for Good Reason in Connection with a Change in Control ($)(7) | |
Jerome Durso | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | 300,956 | | | 300,956 | | | 902,869 | | | 1,805,738 | |
| | | Value of Accelerated Vesting(2) | | | 290,225 | | | 290,225 | | | 351,975 | | | 440,574 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 71,298 | |
| | | Total | | | 591,181 | | | 591,181 | | | 1,290,493 | | | 2,317,609 | |
Sandip Kapadia | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 478,023 | | | 478,023 | |
| | | Value of Accelerated Vesting(2) | | | 144,495 | | | 144,495 | | | 104,975 | | | 223,387 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 35,649 | |
| | | Total | | | 144,495 | | | 144,495 | | | 618,647 | | | 737,059 | |
Richard Kim | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 457,294 | | | 457,294 | |
| | | Value of Accelerated Vesting(2) | | | 132,145 | | | 132,145 | | | — | | | 201,478 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 35,649 | |
| | | Total | | | 132,145 | | | 132,145 | | | 492,943 | | | 694,421 | |
Christian Weyer, M.D., M.A.S. | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 488,011 | | | 488,011 | |
| | | Value of Accelerated Vesting(2) | | | 130,910 | | | 130,910 | | | 68,543 | | | 258,905 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 35,649 | |
| | | Total | | | 130,910 | | | 130,910 | | | 592,203 | | | 782,565 | |
Name | | | | | | Termination Due to Death ($)(4) | | | Termination Due to Disability ($)(5) | | | Termination Without Cause or Resignation for Good Reason ($)(6) | | | Termination Without Cause or Resignation for Good Reason in Connection with a Change in Control ($)(7) | |
Jerome Durso | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | 300,956 | | | 300,956 | | | 902,869 | | | 1,805,738 | |
| | | Value of Accelerated Vesting(2) | | | 290,225 | | | 290,225 | | | 351,975 | | | 440,574 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 71,298 | |
| | | Total | | | 591,181 | | | 591,181 | | | 1,290,493 | | | 2,317,609 | |
Sandip Kapadia | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 478,023 | | | 478,023 | |
| | | Value of Accelerated Vesting(2) | | | 144,495 | | | 144,495 | | | 104,975 | | | 223,387 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 35,649 | |
| | | Total | | | 144,495 | | | 144,495 | | | 618,647 | | | 737,059 | |
Richard Kim | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 457,294 | | | 457,294 | |
| | | Value of Accelerated Vesting(2) | | | 132,145 | | | 132,145 | | | — | | | 201,478 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 35,649 | |
| | | Total | | | 132,145 | | | 132,145 | | | 492,943 | | | 694,421 | |
Christian Weyer, M.D., M.A.S. | | | | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | — | | | — | | | 488,011 | | | 488,011 | |
| | | Value of Accelerated Vesting(2) | | | 130,910 | | | 130,910 | | | 68,543 | | | 258,905 | |
| | | Health Insurance Benefits(3) | | | — | | | — | | | 35,649 | | | 35,649 | |
| | | Total | | | 130,910 | | | 130,910 | | | 592,203 | | | 782,565 | |
Plan Category | | | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants, and Rights | | | Weighted-Average Exercise Price of Outstanding Options, Warrants, and Rights | | | Number of Securities Remaining Available for Future Issuance | | |||||||||
Equity Compensation Plans Approved by Security Holders(1) | | | | | 2,997,685(2) | | | | | $ | 96.92(3) | | | | | | 3,342,486(4) | | |
Equity Compensation Plans Not Approved by Security Holders | | | | | — | | | | | | — | | | | | | — | | |
| | | Amount ($) | | |||
Restricted stock and restricted stock units(1) | | | | | 459,540 | | |
Performance restricted shares and TSR PSUs vesting on December 31, 2020(2) | | | | | 1,168,830 | | |
12-month-vesting performance restricted shares and TSR PSUs(3) | | | | | 2,452,545 | | |
Vesting of stock options(4) | | | | | 316,476 | | |
| | Year Ended December 31, | | | Year Ended December 31, | | ||||||||||||||||||||
| | 2019 | | 2018 | | | 2020 | | 2019 | | ||||||||||||||||
| | (in thousands) | | | (in thousands) | | ||||||||||||||||||||
Audit Fees | | | $ | 1,777 | | | | $ | 1,491 | | | | | $ | 1,615 | | | | $ | 1,777 | | | ||||
Audit-Related Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
Tax Fees | | | | 146 | | | | | 94 | | | | | | 124 | | | | | 146 | | | ||||
All Other Fees | | | | 2 | | | | | 2 | | | | | | 2 | | | | | 2 | | | ||||
Total Fees | | | $ | 1,925 | | | | $ | 1,587 | | | | | $ | 1,741 | | | | $ | 1,925 | | |